A new non-pharmacological vacuum therapy for female sexual dysfunction

Kevin L. Billups; Laura Berman; Jennifer Berman; Michael E. Metz; Margaret E. Glennon; Irwin Goldstein

doi:10.1080/713846826

A new non-pharmacological vacuum therapy for female sexual dysfunction

Kevin L. Billups, Laura Berman, Jennifer Berman, Michael E. Metz, Margaret E. Glennon, Irwin Goldstein

School of Medicine

Research output: Contribution to journal › Article › peer-review

91 Scopus citations

Abstract

Although Female Sexual Dysfunction (FSD) affects 40% of American women, there is no FDA-approved pharmaceutical therapy. The ER OS-CTD™ (Clitoral Therapy Device, UroMetrics, Inc., St. Paul, MN) treatment is the first FDA cleared-to-market therapy for FSD. Clitoral engorgement is believed to play an important role in female sexual arousal and overall sexual satisfaction. The EROS-CTD is a small, battery-powered device designed to enhance clitoral engorgement, increase blood flow to the clitoris, and ultimately improve arousal in women with FSD. The objective of this study was to assess the effectiveness of the EROS-CTD on sexual arousal (genital sensation, vaginal lubrication, ability to reach orgasm, and sexual satisfaction) in normal volunteers and women with FSD.

Original language	English (US)
Pages (from-to)	435-441
Number of pages	7
Journal	Journal of Sex and Marital Therapy
Volume	27
Issue number	5
DOIs	https://doi.org/10.1080/713846826
State	Published - Oct 2001

ASJC Scopus subject areas

Clinical Psychology

Access to Document

10.1080/713846826

Cite this

@article{09f29e2f3dea48dba9f8993abe9c5268,

title = "A new non-pharmacological vacuum therapy for female sexual dysfunction",

abstract = "Although Female Sexual Dysfunction (FSD) affects 40% of American women, there is no FDA-approved pharmaceutical therapy. The ER OS-CTD{\texttrademark} (Clitoral Therapy Device, UroMetrics, Inc., St. Paul, MN) treatment is the first FDA cleared-to-market therapy for FSD. Clitoral engorgement is believed to play an important role in female sexual arousal and overall sexual satisfaction. The EROS-CTD is a small, battery-powered device designed to enhance clitoral engorgement, increase blood flow to the clitoris, and ultimately improve arousal in women with FSD. The objective of this study was to assess the effectiveness of the EROS-CTD on sexual arousal (genital sensation, vaginal lubrication, ability to reach orgasm, and sexual satisfaction) in normal volunteers and women with FSD.",

author = "Billups, {Kevin L.} and Laura Berman and Jennifer Berman and Metz, {Michael E.} and Glennon, {Margaret E.} and Irwin Goldstein",

year = "2001",

month = oct,

doi = "10.1080/713846826",

language = "English (US)",

volume = "27",

pages = "435--441",

journal = "Journal of Sex and Marital Therapy",

issn = "0092-623X",

publisher = "Routledge",

number = "5",

}

TY - JOUR

T1 - A new non-pharmacological vacuum therapy for female sexual dysfunction

AU - Billups, Kevin L.

AU - Berman, Laura

AU - Berman, Jennifer

AU - Metz, Michael E.

AU - Glennon, Margaret E.

AU - Goldstein, Irwin

PY - 2001/10

Y1 - 2001/10

N2 - Although Female Sexual Dysfunction (FSD) affects 40% of American women, there is no FDA-approved pharmaceutical therapy. The ER OS-CTD™ (Clitoral Therapy Device, UroMetrics, Inc., St. Paul, MN) treatment is the first FDA cleared-to-market therapy for FSD. Clitoral engorgement is believed to play an important role in female sexual arousal and overall sexual satisfaction. The EROS-CTD is a small, battery-powered device designed to enhance clitoral engorgement, increase blood flow to the clitoris, and ultimately improve arousal in women with FSD. The objective of this study was to assess the effectiveness of the EROS-CTD on sexual arousal (genital sensation, vaginal lubrication, ability to reach orgasm, and sexual satisfaction) in normal volunteers and women with FSD.

AB - Although Female Sexual Dysfunction (FSD) affects 40% of American women, there is no FDA-approved pharmaceutical therapy. The ER OS-CTD™ (Clitoral Therapy Device, UroMetrics, Inc., St. Paul, MN) treatment is the first FDA cleared-to-market therapy for FSD. Clitoral engorgement is believed to play an important role in female sexual arousal and overall sexual satisfaction. The EROS-CTD is a small, battery-powered device designed to enhance clitoral engorgement, increase blood flow to the clitoris, and ultimately improve arousal in women with FSD. The objective of this study was to assess the effectiveness of the EROS-CTD on sexual arousal (genital sensation, vaginal lubrication, ability to reach orgasm, and sexual satisfaction) in normal volunteers and women with FSD.

UR - http://www.scopus.com/inward/record.url?scp=0034868192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034868192&partnerID=8YFLogxK

U2 - 10.1080/713846826

DO - 10.1080/713846826

M3 - Article

C2 - 11554204

AN - SCOPUS:0034868192

SN - 0092-623X

VL - 27

SP - 435

EP - 441

JO - Journal of Sex and Marital Therapy

JF - Journal of Sex and Marital Therapy

IS - 5

ER -

A new non-pharmacological vacuum therapy for female sexual dysfunction

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this